CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRI MIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPER IDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER

CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRI MIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPER IDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER

The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BUTLER Thomas, JAING Siyi, PALMER James T, LIN Nan-horng, TAN Heow, LAW Brian, SOMANATH Priyanka, KINOSHITA Taisei, LU Daniel, HE Hongyan, WONG Angelina Sau Man
Format: Patent
Sprache:eng ; spa
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to crystalline forms of N-[4-[4- (4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4- [[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2- pyridinecarboxamide (formula (I)). The compound of formula (I) is an irreversible menin-MLL inhibitor for use in the treatment of e.g. cancer, including e.g. lymphoma and leukemia, and autoimmune diseases. The present invention discloses the characterisation of crystalline forms by e.g. XRPD, FTIR, DSC and TGA as well as pharmacological data. La presente invención se refiere a formas cristalinas de N-[4-[4-(4-morfolinil)-7H-pirrolo[2,3-d]pirimidin-6-il]fenil]-4-[ [3(R)-[(1-oxo-2-propen-1-il)amino]-1-piperidinil]metil]-2-piridin acarboxamida (fórmula I) (ver Fórmula). El compuesto de la fórmula (I) es un inhibidor irreversible de menina-MLL para uso en el tratamiento de, por ejemplo, cáncer, incluyendo por ejemplo, linfoma y leucemia, y enfermedades autoinmunes. La presente invención describe la caracterización de formas cristalinas mediante, por ejemplo, XRPD, FTIR, DSC y TGA así como datos farmacológicos.